Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is phase 3 study for prevention of VTE in patients with abdominal surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fondaparinux; PENTA

Criteria

Inclusion criteria:

• Patients aged >=40 years undergoing the following abdominal (diaphragm to pelvic floor) surgery under general anesthesia lasting more than 45 minutes.

• General or urologic surgery

• Cancer surgery

• Gynecologic surgery

• Radical surgery for pelvic malignancy

Exclusion criteria:

• Active, clinically significant bleeding Thrombocytopenia Body weight <40kg